BACKGROUND: The current study aims to investigate the expression of miR-185 in serum and placenta of patients with gestational diabetes mellitus (GDM) and its relationship with insulin resistance. METHODS: The levels of fasting blood glucose (FPG) and fasting insulin (FINS) were measured and the insulin resistance index (HOMA-IR) was calculated. The levels of serum and placental miR-185 were detected by real-time quantitative PCR (qRT-PCR). The relationship between serum and placental miR-185 levels and HOMA-IR was analyzed using Pearson's correlation assay. The diagnostic value of miR-185 was assessed using receiver operating characteristic curve (ROC). RESULTS: Compared with the control group, the serum and placental level of miR-185 was lowest in the severe GDM group and lower in the mild GDM group. Furthermore, the serum levels of FPG, FINS, and HOMA-IR gradually increased in the mild GDM group and the severe GDM group compared to those in the control group. Further study showed that serum and placental miR-185 levels were negatively correlated with HOMA-IR in 156 patients with GDM. ROC analysis showed that the area under the curve (AUC) was 0.927 with the sensitivity and specificity of 0.865 and 0.838, respectively, indicating serum miR-185 could differentiate patients with GDM from controls. CONCLUSIONS: The down-regulation of miR-185 expression in serum and placenta of pregnant women with GDM is negatively correlated with HOMA-IR, suggesting that the decrease of miR-185 may play an important role in the occurrence and development of GDM.
BACKGROUND: The current study aims to investigate the expression of miR-185 in serum and placenta of patients with gestational diabetes mellitus (GDM) and its relationship with insulin resistance. METHODS: The levels of fasting blood glucose (FPG) and fasting insulin (FINS) were measured and the insulin resistance index (HOMA-IR) was calculated. The levels of serum and placental miR-185 were detected by real-time quantitative PCR (qRT-PCR). The relationship between serum and placental miR-185 levels and HOMA-IR was analyzed using Pearson's correlation assay. The diagnostic value of miR-185 was assessed using receiver operating characteristic curve (ROC). RESULTS: Compared with the control group, the serum and placental level of miR-185 was lowest in the severe GDM group and lower in the mild GDM group. Furthermore, the serum levels of FPG, FINS, and HOMA-IR gradually increased in the mild GDM group and the severe GDM group compared to those in the control group. Further study showed that serum and placental miR-185 levels were negatively correlated with HOMA-IR in 156 patients with GDM. ROC analysis showed that the area under the curve (AUC) was 0.927 with the sensitivity and specificity of 0.865 and 0.838, respectively, indicating serum miR-185 could differentiate patients with GDM from controls. CONCLUSIONS: The down-regulation of miR-185 expression in serum and placenta of pregnant women with GDM is negatively correlated with HOMA-IR, suggesting that the decrease of miR-185 may play an important role in the occurrence and development of GDM.